Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRK-170
- Development stage
- Phase 2
- Lead developer
- Toray Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TRK-170 is a small molecule drug developed by Toray Industries. It acts as an antagonist of the integrin alpha-4/beta-1 (α4β1) and integrin alpha-4/beta-7 (α4β7) receptors. These integrins are involved in leukocyte adhesion and migration, processes that play a key role in immune system function and inflammation. By blocking these targets, TRK-170 is designed to modulate immune responses, particularly in diseases characterized by chronic inflammation such as Crohn's disease and other inflammatory bowel diseases. The drug has been evaluated in clinical trials for Crohn's disease but has not advanced beyond Phase 2 development[1][2][3][5].
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)α4β1 (Integrin α4β1)
Beyond the preview
Go deeper on TRK-170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRK-170.